TCGA-ZF-A9RD-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.40341656
- os_event
- true
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-22-0940-01A-01R-0692-07 | — | cohortSQ1 | 0.933 |
| 2 | TCGA-66-2765-01A-01R-0851-07 | — | cohortSQ1 | 0.931 |
| 3 | TCGA-FD-A6TD-01A-51R-A33J-07 | — | — | 0.920 |
| 4 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.918 |
| 5 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.913 |
| 6 | TCGA-33-4566-01A-01R-1443-07 | — | cohortA1 | 0.912 |
| 7 | TCGA-DK-A3WW-01A-22R-A23N-07 | — | — | 0.910 |
| 8 | MNG256 | — | — | 0.908 |
| 9 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.907 |
| 10 | D06FFD0C-80D4-413D-9C83-62D9C163EDAB | — | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.590 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.470 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.320 | Idelalisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |